Media-no-image

​BIO-Europe Spring® 2016 Event in Sweden this April will bring 2,000+ life science executives to Stockholm-Uppsala region

Pressmeddelanden   •   2016-02-03 16:11 CET

Zug, Switzerland and Stockholm, Sweden – February 2, 2016: 

The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4–6, 2016. Organized by EBD Group, the event is co-hosted by Stockholm Business Region and Stockholm Science City Foundation.

The Stockholm-Uppsala region, defined as the three counties of Uppsala, Stockholm and Sörmland, is one of the largest life science clusters in Europe, and Scandinavia's leading life science cluster. It is also one of the world's most productive with an astounding 15–20 new life science companies formed on average in the region each year over the last decade.

“The Stockholm-Uppsala region offers life science companies access to cutting-edge research, unique competence and an infrastructure that brings innovations to patients,” said Ylva Williams, CEO of Stockholm Science City Foundation.“Our strength is in collaboration, where the industry have access to healthcare and patients through test beds. Sweden is an excellent choice for production of biologics, pilots within healthcare as well as for clinical trials. ”

“Stockholm is an active life science cluster with over 600 companies based in the region, including industry leaders such as AstraZeneca and GE Healthcare,” said Anna Chrisman, Group Managing Director, EBD Group. “As an innovation center for stem cell therapies, digital health and drug development R&D, it is the perfect place to hold BIO-Europe Spring.”

BIO-Europe Spring is premier springtime partnering conference serving the global biotechnology industry and is facilitated by EBD Group’s partneringONE®, the gold standard one-to-one networking solution for the life sciences.

One-to-one partnering meetings are a key business strategy that has transformed the drug development industry in bringing together innovators and visionaries with seasoned experts from every corner of the globe. Company presentations by early stage projects, innovative startups, established biotechs and midsize pharma companies are also a focus of the event and enable innovators to present directly to potential investors, pharma and development partners.

International large and midsize pharma companies already confirmed to attend include AbbVie, Alexion Pharmaceuticals, Almirall, Amgen, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Company, Fine Foods & Pharmaceuticals, Ironwood Pharmaceuticals, Johnson & Johnson, LES LABORATOIRES SERVIER, Merck Serono, a division of Merck KGaA, Darmstadt, MSD, Novartis Pharma, Novo Nordisk, Pfizer, Pierre Fabre Medicament, Roche, Sanofi, Takeda Pharmaceutical Company Ltd, and Upsher Smith.

The 2015 edition featured 12,439 one-to-one partnering meetings. Over 2,300 delegates from 1,367 companies representing 53 countries attended. There were 129 company presentations with 2,672 licensing opportunities on offer, and 68 exhibitors at the event.

Registration information for BIO-Europe Spring is available online.

# # #

Additional links and information:

Follow BIO-Europe Spring 2016 on Twitter: @EBDGroup (hashtag: #BES16).

Online Press Kit service for BIO-Europe Spring 2016 is available from Virtual Press Office/PR Newswire to enhance your public relations efforts.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Innovation Organization (BIO)
BioPharm America™, the fastest growing partnering event in North America
Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® Group
Biolatam®,facilitating partnering among global life sciences executives in Latin America’s vibrant life science hubs

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

Contact:
Erin Righetti
EBD Group
+1 760 930 0500
erighetti@ebdgroup.com

Stockholm Life Solna-Stockholm är ett nav för forskning och utveckling inom life science i Hagastaden. Området där Solna och Stockholm möts är redan idag ett kraftfullt centrum där akademisk kunskap, företag samt hälso- och sjukvården samarbetar för att bidra till bättre hälsa och livskvalitet.

Zug, Switzerland and Stockholm, Sweden – February 2, 2016: The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4–6, 2016. Organized by EBD Group, the event is co-hosted by Stockholm Business Region and Stockholm Science City Foundation.

Läs vidare »
Dpqtbmx0nmnvrxzx1ati

Stockholm Science City Newsletter - January 2016

Nyheter   •   2016-01-29 15:48 CET

Tools of Science, research on openness, upcoming seminars within life science and much more. Don't miss the January newsletter from Stockholm Science City Foundation.

Media-no-image

Diabetes Tools TriabetesClinic är nominerad till Global Mobile Awards 2016 på prestigefyllda Mobile World Congress

Pressmeddelanden   •   2016-01-26 09:16 CET

Stockholm den 21 januari 2016 – Diabetes Tools har nominerats till Best Mobile Innovation for Health av GSMA 2016 Global Mobile Awards för sitt distansvårds- och beslutsstödsystem TriabetesClinic. Systemet sätter medicinska appar i centrum av vårdprocessen för barn med insulinberoende diabetes, både på sjukhuset och för distansvård i hemmamiljön.

"TriabetesClinic för barn kombinerar mobila appar för egenvård med mobila kliniklösningar på online-verktyg för att förenkla och digitalt stödja vården runt varje barn med diabetes", säger Diabetes Tools VD och koncernchef Anders Weilandt. "Att bli utvald av Glomo Awards domarkommitté visar att den digitala hälsosektorn är på frammarsch. Digital hälsa har dock fortfarande en lång väg kvar till fullständig kommersialisering. Denna nominering stärker vårt teams redan betydande uthållighet och fokusering för att nå hela vägen fram till mål."

"Grattis alla nominerade till 2016 Glomo Awards", säger Michael O'Hara, Chief Marketing Officer, GSMA "Med mer än 930 bidrag i år – Ett nytt rekord – så är konkurrensen större än någonsin, vilket speglar den enorma mångfalden och innovationstakten i den mobila världen. Vi är särskilt glada över att fira 21 år för denna utmärkelse med ett nytt dynamiskt format för att erkänna och hylla betydelsefulla prestationer under hela Mobile World Congress."

Glomo Awards belönar prestationer och innovationer inom mobilbranschen och omfattar mer än 40 utmärkelser i åtta kategorier. Resultaten för 2016 års vinnare i kategorin Connected Life Awards kommer att tillkännages under Mobile World Congress, världens största utställning och konferens inom mobilindustrin som hålls i Barcelona, Spanien 22-25 februari. För mer information besök

www.globalmobileawards.com/nominees2016.

Triabetes och TriabetesClinic är varumärken som tillhör Diabetes Tools Sweden AB.

Om Diabetes Tools
Diabetes Tools är ett svenskt medicintekniskt företag som förenklar vardagen för alla inblandade i diabetesvården. Programvarutjänsten TriabetesClinic kombinerar säkert appar (för smartphones och surfplattor), online-konton och webbgränssnitt för att förändra och förbättra diabetesvården.

Diabetes Tools utsågs till ”Årets MedTechföretag 2014" av Swedish Medtech Association. Diabetes Tools är certifierade mot ISO 13485, en standard för utveckling av medicintekniska produkter och tillhörande tjänster. Triabetes är en CE-märkt medicinsk programvara som är registrerad för försäljning inom EU. Diabetes Tools är privatägt och baserat i Stockholm. Mer information finns på www.diabetestools.se.

Presskontakt: Catherine Dowdell, PR-och kommunikationschef, E-post: press@diabetestools.se Telefon: 08 5252 3511

Stockholm Life Solna-Stockholm är ett nav för forskning och utveckling inom life science i Hagastaden. Området där Solna och Stockholm möts är redan idag ett kraftfullt centrum där akademisk kunskap, företag samt hälso- och sjukvården samarbetar för att bidra till bättre hälsa och livskvalitet.

Diabetes Tools har nominerats till Best Mobile Innovation for Health av GSMA 2016 Global Mobile Awards för sitt distansvårds- och beslutsstödsystem TriabetesClinic. Systemet sätter medicinska appar i centrum av vårdprocessen för barn med insulinberoende diabetes, både på sjukhuset och för distansvård i hemmamiljön.

Läs vidare »
Dpqtbmx0nmnvrxzx1ati

Stockholm Science City Newsletter - December 2015

Nyheter   •   2015-12-18 15:06 CET

Protein science and production - a Swedish strength, Reflections of Stacey Chang, an Eisenhower Fellow visiting Stockholm Science City and academic core facilities in the region - those are a few of the news in the last Stockholm Science City Newsletter for 2015. Happy holidays!

Dpqtbmx0nmnvrxzx1ati

Stockholm Science City Newsletter - November 2015

Nyheter   •   2015-11-26 13:41 CET

Read about digital health in Japan, a planned sport hall in Hagastaden and Tools of Science. Among other things. Check out the latest newsletter from Stockholm Science City Foundation.

Dpqtbmx0nmnvrxzx1ati

Stockholm Science City Newsletter - October 2015

Nyheter   •   2015-11-09 09:26 CET

Read more about the Stockholm Medical Biobank, about Swedish success in the iGEM competition, the BIO-X call for proposals as well as other news from the life science scene in Stockholm in Stockholm Science City's latest newsletter.

Media-no-image

Complex generics specialist Xbrane acquires Italian Primm Pharma and signs Iranian pharmaceutical deal

Pressmeddelanden   •   2015-10-14 11:20 CEST

Xbrane, a commercial phase Swedish biopharmaceutical company specialized in High Demand Complex Generics, today announced the acquisition of Italian based Primm Pharma and the completion of a breakthrough distribution deal for its lead biogeneric pharmaceutical Spherotide with the Iranian company Pooyesh Darou.

Primm Pharma is specialized in the development and production of pharmaceutical formulations for slow release injections and has a portfolio currently consisting of five slow release biogeneric candidates. The lead product Spherotide will primarily be used for the treatment of prostate cancer and endometriosis and will be available in emerging markets from mid 2017.

“Through the acquisition of Primm Pharma we are able to broaden our expertise within the field of High Demand Complex Generics. Primm Pharma has unique expertise in microsphere-based drugs and a lead product Spherotide that we believe will become the world's first slow-release biogeneric for a sizable prostate cancer and endometriosis drug, commented Martin Åmark, CEO of Xbrane.

The Primm Pharma acquisition extends Xbrane’s current portfolio to 8 development candidates. It reflects the company’s mission to bring affordable biogenerics and biosimilars to patients suffering from critical diseases in underserved markets. Xbrane estimates that the combined market for the original drugs of which the company´s portfolio of complex generics addresses is around USD10 billion and, as a first step, earlier this month signed an agreement with Pooyesh Darou for the introduction of Spherotide into the Middle East market. The deal brings Xbrane potential annual revenue of USD10 million.

“We are delighted to have signed this agreement and to get the opportunity to work with Pooyesh Darou, one of the leading biotech companies in the Middle East. Pooyesh Darou has an impressive track record of reaching near full penetration in Iran on all introduced biogeneric products. Iran is a very interesting market with a population of 80 million, of which more than 90 percent are covered by the publicly-funded health care and we see it as an ideal first market for our high demand complex generics,” added Åmark.

About Xbrane
Xbrane is a commercial phase Swedish Biopharmaceutical Company specialized in High Demand Complex Generics. Xbrane has world leading expertise in developing biogenerics for injectable slow release drugs and proprietary high-yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the company’s portfolio of High Demand Complex Generics.

Xbranes’s headquarters is located in Stockholm and the company’s in-house research and development facilities are in Sweden and Italy.

The company has a board with vast experience from big-pharma companies including Professor Alf Lindberg, former secretary of the Nobel Committee, Head of R&D at Wyeth Vaccines, EVP of R&D at Sanofi Pasteur and lead developer of Prevnar, Prof. Maris Hartmanis, formerly CEO of Medivir and BioPhausia, Karin Wingstrand formerly Global Head and Vice President of Clinical Development at AstraZeneca and Prof. Peter Edman, Orexo, with previous senior positions at Sobi, Biovitrum, AstraZeneca, Astra and Pharmacia.

For further information, please contact:
Martin Åmark, CEO, Xbrane, phone: +46 (0) 763-093 777, martin.amark@xbrane.com

Stockholm Life Solna-Stockholm är ett nav för forskning och utveckling inom life science i Hagastaden. Området där Solna och Stockholm möts är redan idag ett kraftfullt centrum där akademisk kunskap, företag samt hälso- och sjukvården samarbetar för att bidra till bättre hälsa och livskvalitet.

Xbrane, a commercial phase Swedish biopharmaceutical company specialized in High Demand Complex Generics, today announced the acquisition of Italian based Primm Pharma and the completion of a breakthrough distribution deal for its lead biogeneric pharmaceutical Spherotide with the Iranian company Pooyesh Darou.

Läs vidare »
Bltqpffypaf9odtixptm

Stockholm Life Newsletter - September 2015

Nyheter   •   2015-09-30 10:20 CEST

Read about the Health Hack Academy, Honey from Humlegården, Digital Health STHLM and lots more in the September newsletter of Stockholm Life.

Q06sf8areb45q7if4tbr

Digital Health Days 2015 in figures - a super brief recap

Nyheter   •   2015-09-25 13:01 CEST

Did you miss Digital Health Days 2015? Or wish to see any of the presentations again?

Q06sf8areb45q7if4tbr

Digital Health Days: ​Catch up on the latest developments in digital health in Europe’s leading hub

Pressmeddelanden   •   2015-09-18 14:27 CEST

Some of the most influential, international digital health experts as well as a number of interesting International and Nordic companies and investors will attend the Digital Health Days in Stockholm on September 23-24, 2015.

Kommande evenemang 1 evenemang

14 Mar 07:45

Frukostseminarium: Hur vinklar du projektet för att intressera investerare?

2016-03-14, 07:45 - 09:00
Wenner-Gren Center plan 24 (ta hissarna till plan 23). Sveavägen 166.

Kontaktpersoner 4 kontaktpersoner

  • Presskontakt
  • Kommunikationschef
  • Marknadsföring och kommunikation
  • anna.frejd@ssci.se
  • +46 705 39 00 79
  • +46 8 522 110 40
Marketing and Communications Director

Om Stockholm Life Solna-Stockholm

Stockholm Life Solna-Stockholm är ett nav för forskning och utveckling inom life science i Hagastaden.

Stockholm Life är en del av ett nytt stadsområde som växer fram i gränsen mellan Solna och Stockholm – i storstadens puls och med naturen om hörnet. Inom området görs stora investeringar i bostäder, life science-fastigheter och kommunikation för att fylla det med service, kultur och möjligheter till rekreation.

Adress

  • Stockholm Life Solna-Stockholm
  • STOCKHOLM SCIENCE CITY Wenner-Gren Center, Sveavägen 166
  • 113 46 Stockholm
  • Vår hemsida